Financial Gravity Asset Management’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Financial Gravity Asset Management’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-17	Closed	-$340	–	1730
2022 Q4	$340	Buy	+17	New	+$274	﹤0.01%	856

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Financial Gravity Asset Management's CALT Position: Q1 2023 in Review

Financial Gravity Asset Management sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q1 2023, closing a stake of 17 shares — an estimated $340 sold.

Financial Gravity Asset Management first reported a position in CALT in Q4 2022 and held it in 1 quarter. The position peaked at $340 in Q4 2022. 14 funds tracked by Wall St. Rank hold CALT as of Q1 2023.

Financial Gravity Asset Management reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q1 2023 after selling out during the quarter.
Financial Gravity Asset Management sold 17 Calliditas Therapeutics AB American Depositary Shares shares in Q1 2023, an estimated $340.
Financial Gravity Asset Management first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q4 2022 and held it in 1 quarter.
Financial Gravity Asset Management's Calliditas Therapeutics AB American Depositary Shares position peaked at $340 in Q4 2022.
14 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q1 2023.

Based on Financial Gravity Asset Management's 13F filing for Q1 2023, filed 12 May 2023.